Karyopharm Therapeutics Reports Q4 Loss Narrower than Expected
NEWTON, Mass. - Karyopharm Therapeutics Inc. (KPTI) reported a narrower-than-expected loss for the fourth quarter of 2023.
Key Highlights:
* Net loss: $30.8 million, or 24 cents per share
* Revenue: $30.5 million
* Analysts' estimate: Loss of 26 cents per share
Annual Results:
* Net loss: $76.4 million, or 93 cents per share
* Revenue: $145.2 million
Outlook:
* Full-year revenue guidance: $140 million to $155 million
Karyopharm Therapeutics' results surpassed analysts' expectations and the company remains optimistic about its future prospects.